Barinthus Biotherapeutics (STU:2AB) Net Change in Cash: €-24.18 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2AB Barinthus Biotherapeutics PLC STU:2AB
14 GF Score
Price €0.48
GF Value €0.93
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics Net Change in Cash?

Barinthus Biotherapeutics STU:2AB 14 Net Change in Cash is €-24.18 Mil as of Jun. 2026. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.93. The stock has 1 warning sign investors should review.

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Barinthus Biotherapeutics's Net Change in Cash for the three months ended in Jun. 2026 was €-6.56 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2026 was €-24.18 Mil.

Barinthus Biotherapeutics Net Change in Cash Historical Data

* Premium members only.

The historical data trend for Barinthus Biotherapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Barinthus Biotherapeutics Net Change in Cash Chart

Barinthus Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Change in Cash
Get a 7-Day Free Trial 151.15 -18.57 -47.95 -28.35 -34.63

Barinthus Biotherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.09 -10.32 -3.26 -4.03 -6.56
STU:2AB
14GF Score
Barinthus Biotherapeutics PLC STU:2AB
Net Change in Cash is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Barinthus Biotherapeutics Net Change in Cash Calculation

Barinthus Biotherapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2025 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-40.974+0.355+0.002+5.989
=-34.63

Barinthus Biotherapeutics's Net Change in Cash for the quarter that ended in Jun. 2026

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-7.023+0.053+0+0.409
=-6.56

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-24.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Change in Cash →
What does a Net Change in Cash of €-24.18 Mil mean?
Barinthus Biotherapeutics (STU:2AB) has a Net Change in Cash of €-24.18 Mil as of Jun. 2026. The net change in cash is the total change in cash and equivalents between the current period and the past period. View historical data for Barinthus Biotherapeutics and its competitors.
Is Barinthus Biotherapeutics' Net Change in Cash too high?
Barinthus Biotherapeutics' current Net Change in Cash is €-24.18 Mil. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Net Change in Cash compare to CRVO and ALGS?
Barinthus Biotherapeutics' Net Change in Cash of €-24.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Change in Cash for a Biotechnology company?
A good Net Change in Cash depends on the Biotechnology industry context. However, Net Change in Cash should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Change in Cash mean?
A high Net Change in Cash can signal that a stock is expensive relative to its fundamentals. The net change in cash is the total change in cash and equivalents between the current period and the past period. View historical data for Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current Net Change in Cash is €-24.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current Net Change in Cash of €-24.18 Mil. The stock's GF Value™ is €0.93, compared to a current price of €0.48 — trading 48.4% below its estimated fair value. The current Net Change in Cash is €-24.18 Mil. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Change in Cash calculated?
Net Change in Cash is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Net Change in Cash is €-24.18 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of €0.48 is trading 48.4% below its estimated GF Value™ of €0.93.

Key valuation signals for STU:2AB:

  • Net Change in Cash: €-24.18 Mil
  • GF Value™: €0.93 vs. price of €0.48 (48.4% below fair value)
  • GF Score™: 14/100 with 1 warning sign

No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Barinthus Biotherapeutics Business Description

Other Exchanges BRNS:USA
Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score

Get the complete analysis for STU:2AB

Net Change in Cash is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.48
Price
€0.93
GF Value